NewMeco Obtains Product Approval for Botulinum Toxin "NewLux" in El Salvador

Establishing a Strategy to Leverage Meditox's Local Sales Network

Meditoxt's affiliate, NewMeco, announced on November 26 that it has obtained product approval for its botulinum toxin formulation "NewLux" from the Salvadoran National Directorate of Medicines (SRS).

NewLux. NewMeco

El Salvador, a major emerging country in Central and South America, is one of the leading nations experiencing rising demand for aesthetic procedures such as botulinum toxin and fillers, driven by economic growth and the influence of social media. Meditox completed registration of its botulinum toxin product "Meditoxin" (export name "Neuronox") in 2009 and its hyaluronic acid filler "Neuramis" in 2020. Based on the synergy between its botulinum toxin and filler products, NewMeco has continued its growth trajectory, and this year expects local sales to increase by more than 50% compared to the previous year.

To ensure the successful market entry of "NewLux," NewMeco is leveraging Meditox's local sales network and developing optimal, customized marketing strategies, including promotions linked with "Neuramis."

A NewMeco representative stated, "With approval in El Salvador, our efforts to expand 'NewLux' across Central and South America have gained further momentum. We will continue to enter major countries in the region and elevate the status of our global toxin brand."

Meanwhile, "NewLux," a next-generation botulinum toxin formulation produced using the latest processes to improve yield and quality, is accelerating its global expansion based on its product competitiveness. Starting with Peru last year, the company has entered Bolivia and the Dominican Republic, pioneering the Central and South American market, and is also expanding into European and Asian markets such as Thailand, Georgia, and Moldova.

This content was produced with the assistance of AI translation services.